Fox Chase Cancer Center to Lead NCCN-supported Phase II Lung Cancer Study with Focus on Non-Smokers

Oct 29, 2019 | Lung Cancer, National Comprehensive Cancer Network, NCCN, Oncology

Fox Chase Cancer Center to Lead NCCN-supported Phase II Lung Cancer Study with Focus on Non-Smokers

The National Comprehensive Cancer Network (NCCN) Oncology Research Program (OPR) will support a Phase II randomized trial for lung cancer patients titled TH-138. Joseph Treat, MD, Professor, Department of Hematology/Oncology, Fox Chase Cancer Center will serve as Principal Investigator.

Non-Smokers who have Lung Cancer

A dangerous disease, lung cancer represents a leading cause of death worldwide. Often caused by cigarette smoking, nearly 20% fall to lung cancer that never smoked. Non-smoking related lung cancers have a different molecular profile than those in smokers, such as mutations in the epiderma growth factor receptor (EGFR) and have a variable response to checkpoint inhibitors reports the recent press release highlighting the study.

The Study

The study, titled TH-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab with or without atezolizumab in stage IV non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked, will also include co-investigators Hossein Borghaei, DO and J Nicholas Bodor, MD, PhD and J. Nicholas Bodor, MD, PhD, also from Fox Chase Cancer Center along with Jyoti Patel,  MD incoming Assistant Director for Clinical Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.  This study is funded by commercial sponsor Genentech (Roche).

The 31 months study focuses on those patients whose tumors include an EGFR mutation, or who are never smokers. The sponsor and clinical investigators seek to determine if the anti-PD-L1 inhibitor atezolizumab plus carboplatinpemetrexed, and bevacizumab will improve progression-free survival and overall survival in this population, as compared to carboplatin, pemetrexed, and bevacizumab.  The team seeks to enroll 100 patients from across 15-20 cancer centers. Open to those 18 and older who have not been previously treated with any systemic therapy other than tyrosine kinase inhibitors (TKIs).

Who is NCCN?

NCCN is an alliance of 28 cancer centers in America, most of which are designated by the National Cancer Institute as comprehensive cancer centers. A non-profit organization based in Pennsylvania, they support critical clinical trials as well as publish peer-reviewed medical journal of the National Comprehensive Cancer Network. Member institutions are included here. NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world.

Sponsor

Although Genentech is paying for the primary costs, the formally acknowledged sponsor is Fox Chase Cancer Center at Temple Health Lewis Katz School of Medicine.

Lead Research/Investigators

Joseph Treat, MD, Professor, Department of Hematology/Oncology, Fox Chase Cancer Center

Hossein Borghaei, DO, Fox Chase Cancer Center

J Nicholas Bodor, MD, PhD, Fox Chase Cancer Center

Jyoti Patel, MD incoming Assistant Director for Clinical Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Call to Action: If you or a loved one has been diagnosed with lung cancer and is not a smoker, this important study may be relevant to understand and possibly even participate in. TrialSite News suggests contacting the Fox Change Cancer Center team if interested.

0 Comments

Pin It on Pinterest